MFMarie Fisk

Marie Fisk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marie Fisk has a total of 253 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Participant experience and the use of a decentralised trial model to support recruitment in the OPACE trial: a pragmatic double‑blind, randomised placebo controlled trial of continued versus discontinued azithromycin prophylaxis in COPD.

    by Marie Fisk, Gbenga Adesoye, Zehra Yilmaz, Pedro Avila, Freddy Frost, Francis Appiagyei, Hudson Mumbole, Frances Early, David Anderson, Graham Miller, et al.

    Background: The patient voice is central to clinical trial design, yet trial recruitment remains challenging. Trials must adopt accessible approaches to improve engagement. We report participant feedback from the NIHR OPACE trial and the impact of introducing a decentralised delivery model on recruitment. Methods: OPACE (Optimising azithromycin prevention treatment to reduce COPD exacerbations) is a UK pragmatic trial (target n=618) evaluating continuation vs discontinuation of azithromycin prophylaxis in COPD. Participant experience is assessed through a baseline questionnaire, end‑of‑trial questionnaire and 3‑month interviews in a subsample of participants. Baseline findings are presented. To support recruitment, alongside ~40 research sites, a pilot decentralised model was introduced. The Optimum Patient Care GP network enabled honorary GP staff to assess eligibility, conduct phone consultations and link interested patients with the central trial team. Results: Baseline questionnaires were completed by 135 participants; 75% had not previously taken part in research, 62% identified as disabled, 10% were carers and 34% lived alone. Participant preferences: 64% preferred taking part from home, 33% preferred mixed home and site visits, and 10% preferred site visits only. Home delivery of medication was rated very helpful by 93%. Interviews highlighted support from the trial team as key to participation. The decentralised model significantly increased recruitment, increasing from 7.2 (±3.3)/month to 19.5 (±0.7)/month, p<0.001, and will continue as a recruitment model. Conclusions: Patients value the option to participate from home. A decentralised model alongside traditional site delivery can enhance recruitment and is well suited to pragmatic trials focused on clinical effectiveness.

  • Open Access

    GOLD 2026 COPD ABE assessment tool to identify individuals at high risk in a UK multicentre COPD cohort (ERICA)

    by Gbenga Adesoye, Alastair Watson, Tengyu Zhao, Charlotte E Bolton, Chris J Smith, Jonathan Fuld, Carmel McEniery, Joseph Cheriyan, John Cockcroft, William MacNee, et al.

    Identifying people with chronic obstructive pulmonary disease (COPD) who are at high risk of significant health events such as exacerbations and hospital admissions is clinically important to guide optimisation of preventative interventions. We evaluated the utility of the Global Initiative for Obstructive Lung Disease (GOLD) 2026 ABE assessment tool which stratifies based on exacerbations or symptoms to distinguish these patients at high risk. Methods: 664 participants from the ERICA ( E valuation of the R ole of I nflammation in C hronic A irways Disease) COPD cohort were classified into GOLD ABE groups using both the Chronic Airways Assessment Tool (CAAT) score and the modified Medical Research Council (mMRC) breathlessness scale to define the degree of symptoms. National Health Service hospital episode statistics data were prospectively collected for a median follow-up of 4.75 years. Hospital admissions, including for acute exacerbations of COPD (H-AECOPD (hospitalised acute exacerbations of COPD)), were evaluated. Logistic regression analyses with ORs adjusted for potential confounding factors were performed. Results: Using CAAT, n=43/182/439 (7%/27%/66%) of participants were in groups A, B and E, respectively. By mMRC, n=144/81/439 (22%/12%/66%) were in groups A, B and E. The ABE tool derived using both CAAT and mMRC predicted H-AECOPD over follow-up. For group B versus group A by CAAT, the OR was 3.72 (95% CI 1.09 to 12.73, p=0.04), and for group E versus group A the OR was 8.13 (95% CI 2.45 to 26.92, p<0.001). By mMRC, for group B versus group A the OR was 2.69 (95% CI 1.36 to 5.32, p=0.005) and for group E versus group A the OR was 4.05 (95% CI 2.38 to 6.05, p<0.001). Conclusions: In this prospective real-world UK cohort, the simple GOLD 2026 ABE tool identified patients with high-risk COPD for severe exacerbations (H-AECOPD). The differences in groups A and B classification depending on whether the CAAT score or mMRC scale is used have clinical implications that need consideration.

  • Open Access

    Dysregulation of lipid mediators in patients with frequent exacerbations of COPD

    by Marie Fisk, Esteban A. Gomez, Yuan Sun, Monika Mickute, Carmel McEniery, John R. Cockcroft, Charlotte Bolton, Jonathan Fuld, Joseph Cheriyan, Yasmin, et al.

    Introduction: Specialised pro-resolving mediators (SPMs) are endogenously produced lipid mediators (LMs) that regulate the propagation of inflammation and promote tissue repair. We hypothesised that SPM production is dysregulated in COPD and is associated with disease severity, defined by patients with stable COPD (no exacerbations)versuspatients with frequent exacerbations.Methods: LMs were measured in plasma samples from patients with COPD (stable patients and patients with frequent exacerbations) and from healthy controls, matched for age, sex and body mass index, using liquid chromatography–tandem mass spectrometry (LC-MS/MS). The LM profiles of controls were compared with those of stable COPD patients, and the LM profiles of stable COPD patients were compared with those of COPD patients with frequent exacerbations. We explored whether or not there was an association between LM profile and ever having a severe COPD exacerbation over 4.1 years of follow-up. Data are presented as mean±semin pg·mL−1for LMs, or mean±sd.Results: 49 stable COPD patients had increased levels of pro-inflammatory mediators and some SPMs, compared with 28 controls (prostaglandin (PG)D2: 13.97±2.44versus0.53±0.13; pversus59.84±20.25; p2(3.07±0.97versus13.97±2.44; pversus34.53±8.95; pversus226.83±23.84; p9 L−1versus4.28±1.60×109 L−1; p=0.004). Among patients with frequent exacerbations, D-resolvin levels were independently inversely associated with occurrence of severe exacerbation (OR 0.88, 95% confidence interval (CI) 0.79–0.97; p=0.03) during follow-up.Conclusion: These findings demonstrate distinct LM profiles of stable COPD patients and patients with frequent exacerbations. In those with exacerbations, D-resolvins were downregulated, compared with stable COPD patients, and associated with future risk of severe exacerbations during follow-up. Further work is needed to understand these findings.


  • Dysregulation of lipid mediators in exacerbator phenotype of chronic obstructive pulmonary disease

    by Marie Fisk, Jesmond Dalli

    BioStudies – one package for all the data supporting a study

  • Open Access

    Flow-mediated dilatation: learning curve study with a novice operator

    by Arko S. Dhar, Marie Fisk, Carmel M. McEniery, Domonkos Cseh

    Introduction: Brachial artery flow-mediated dilatation (FMD) is commonly measured to assess endothelial function in experimental and clinical research studies. However, attaining reproducible results can be challenging, especially among inexperienced operators. Until now, no detailed learning curve study of novice operators has been published. Methods: We assessed the learning curve of FMD measurement in one novice operator. Following a one-week basic training period, the operator performed duplicate measurements on 6-8 individuals per week, for six weeks. The operator followed the recommendations of the most recent FMD measurement guideline. Duplex ultrasound was used for the simultaneous and continuous measurement of brachial artery diameter and local blood flow velocity. Following a 1-minute recording of baseline diameter (D), FMD was measured after a 5-minute period of occlusion of the proximal forearm vessels. Inter-session coefficient of variation (CV) values for D and FMD were calculated for each week. Results: The majority of participants did not have any cardiovascular disease history. The number of volunteers assessed each week were the following: 8, 7, 7, 6, 7, 7 individuals, from week 1 to week 6. CV values for both D and FMD exhibited a decreasing trend over the training period, ending at 1.73% for D and 14.24% for FMD at week 6. The CV values at week 6 were within the range outlined in the most recent FMD guideline for proficiency. Conclusions: Within a reasonable timeframe, and with careful adherence to measurement guidelines, the attainment of sound reproducibility in FMD measurements by a novice operator is feasible.


  • Open Access

    Circulating testosterone levels and health outcomes in chronic obstructive pulmonary disease: results from ECLIPSE and ERICA

    by Holly Pavey, Michael I Polkey, Charlotte E Bolton, Joseph Cheriyan, Carmel M McEniery, Ian Wilkinson, Divya Mohan, Richard Casaburi, Bruce E Miller, Ruth Tal-Singer, et al.

    The relationship of circulating testosterone levels with health outcomes in people with chronic obstructive pulmonary disease (COPD) is unknown. Aim To determine whether serum testosterone levels predict hospitalised acute exacerbations of COPD (H-AECOPD), cardiovascular disease outcome, and mortality in people with COPD. Methods Separate analyses were carried out on two observational, multicentre COPD cohorts, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) and Evaluation of the Role of Inflammation in Chronic Airways Disease (ERICA), both of which had serum testosterone measured using a validated liquid chromatography assay at the same laboratory. Data from 1296 male participants in ECLIPSE and 386 male, 239 female participants in ERICA were analysed. All analyses were sex-specific. Multivariate logistic regression was used to determine associations with H-AECOPD during follow-up (3 years ECLIPSE, 4.5 years ERICA), a composite endpoint of cardiovascular hospitalisation and cardiovascular death, and all-cause mortality. Results Mean (SD) testosterone levels were consistent across cohorts; 459 (197) and 455 (200) ng/dL for males in ECLIPSE and ERICA, respectively, and in ERICA females: 28 (56) ng/dL. Testosterone was not associated with H-AECOPD (ECLIPSE: OR: 0.76, p=0.329, ERICA males: OR (95% CI): 1.06 (0.73 to 1.56), p=0.779, ERICA females: OR: 0.77 (0.52 to 1.12), p=0.178) or cardiovascular hospitalisation and death. Testosterone was associated with all-cause mortality in Global Initiative for Obstructive Lung Disease (GOLD) stage 2 male patients only, in ECLIPSE (OR: 0.25, p=0.007) and ERICA (OR: (95% CI): 0.56 (0.32 to 0.95), p=0.030). Conclusions Testosterone levels do not relate to H-AECOPD or cardiovascular outcome in COPD, but are associated with all-cause mortality in GOLD stage 2 COPD male patients, although the clinical significance of this finding is uncertain.


  • Top Cited Papers
    Open Access

    Niclosamide—A promising treatment for COVID‐19

    by Shivani Singh, Anne Weiss, James Goodman, Marie Fisk, Spoorthy Kulkarni, Ing Lu, Joanna Gray, Rona Smith, Morten Sommer, Joseph Cheriyan

    Vaccines have reduced the transmission and severity of COVID‐19, but there remains a paucity of efficacious treatment for drug‐resistant strains and more susceptible individuals, particularly those who mount a suboptimal vaccine response, either due to underlying health conditions or concomitant therapies. Repurposing existing drugs is a timely, safe and scientifically robust method for treating pandemics, such as COVID‐19. Here, we review the pharmacology and scientific rationale for repurposing niclosamide, an anti‐helminth already in human use as a treatment for COVID‐19. In addition, its potent antiviral activity, niclosamide has shown pleiotropic anti‐inflammatory, antibacterial, bronchodilatory and anticancer effects in numerous preclinical and early clinical studies. The advantages and rationale for nebulized and intranasal formulations of niclosamide, which target the site of the primary infection in COVID‐19, are reviewed. Finally, we give an overview of ongoing clinical trials investigating niclosamide as a promising candidate against SARS‐CoV‐2.


  • Open Access

    Sustainable medicines development and use: Our collective responsibility for action to mitigate the natural world crisis

    by Marie Fisk, Anna Zecharia, Rupert Payne, Michael Okorie, Stephen Alexander, Emma Baker, Serge Cremers


  • Open Access

    Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19

    by Marie Fisk, Magnus Althage, Sven Moosmang, Peter J. Greasley, Andrew P. Cope, David Rw. Jayne, James Galloway, Frances Hall, Ian B. Wilkinson, Philip Ambery, et al.


  • Open Access

    Quantitative18F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD

    by Laurence Vass, Marie Fisk, Joseph Cheriyan, Divya Mohan, Julia Forman, Adelola Oseni, Anand Devaraj, Kaisa M. Mäki-Petäjä, Carmel M. McEniery, Jonathan Fuld, et al.

    Rationale: COPD and smoking are characterised by pulmonary inflammation.18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging may improve knowledge of pulmonary inflammation in COPD patients and aid early development of novel therapies as an imaging biomarker.Objectives: To evaluate pulmonary inflammation, assessed by FDG uptake, in whole and regional lung in “usual” (smoking-related) COPD patients, alpha-1 antitrypsin deficiency (α1ATD) COPD patients, smokers without COPD and never-smokers using FDG PET/CT. Secondly, to explore cross-sectional associations between FDG PET/CT and systemic inflammatory markers in COPD patients and repeatability of the technique in COPD patients.Methods: Data from two imaging studies were evaluated. Pulmonary FDG uptake (normalised Ki; nKi) was measured by Patlak graphical analysis in four subject groups: 84 COPD patients, 11 α1ATD-COPD patients, 12 smokers and 10 never-smokers. Within the COPD group, associations between nKiand systemic markers of inflammation were assessed. Repeatability was evaluated in 32 COPD patients comparing nKivalues at baseline and at 4-month follow-up.Results: COPD patients, α1ATD-COPD patients and smokers had increased whole lung FDG uptake (nKi) compared with never-smokers (0.0037±0.001, 0.0040±0.001, 0.0040±0.001versus0.0028±0.001 mL·cm−3·min−1, respectively, pi(β=0.30, p=0.02) in multivariate analysis adjusted for current smoking, forced expiratory volume in 1 s % predicted, systemic neutrophils and C-reactive protein levels. Mean percentage difference in nKibetween the baseline and follow-up was 3.2%, and the within subject coefficient of variability was 7.7%.Conclusions: FDG PET/CT has potential as a noninvasive tool to enable whole lung and regional quantification of FDG uptake to assess smoking- and COPD-related pulmonary inflammation.